Ipilimumab and nivolumab: the 'new kid on the block' in advanced angiosarcoma

ImmunotherapyAhead of Print EditorialIpilimumab and nivolumab: the ‘new kid on the block’ in advanced angiosarcomaTarek Assi, Rebecca Ibrahim, Toni Ibrahim, Rita Khoury & Axel Le CesneTarek Assi *Author for correspondence: Tel.: +330 033 767 129 224; E-mail Address: tarek.assi@gustaveroussy.frhttps://orcid.org/0000-0002-5579-5264Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceSearch for more papers by this author, Rebecca IbrahimDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceSearch for more papers by this author, Toni IbrahimDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceSearch for more papers by this author, Rita KhouryDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceSearch for more papers by this author & Axel Le CesneDivision of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, FranceSearch for more papers by this authorPublished Online:10 Aug 2023https://doi.org/10.2217/imt-2023-0110AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: angiosarcomacancercheckpointimmunotherapysarcomasoft tissueReferences1. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 11(10), 983–991 (2010).Crossref, Medline, Google Scholar2. Sturm EC, Marasco IS, Katz SC. Multidisciplinary management of angiosarcoma – a review. J. Surg. Res. 257, 213–220 (2021).Crossref, Medline, CAS, Google Scholar3. Penel N, Bui BN, Bay J-O et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26(32), 5269–5274 (2008).Crossref, Medline, CAS, Google Scholar4. Soft Tissue Sarcoma. National Comprehensive Cancer Network, Plymouth Meeting, PA, USA (2023).Google Scholar5. Tawbi HA, Burgess M, Bolejack V et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18(11), 1493–1501 (2017).Crossref, Medline, CAS, Google Scholar6. D'Angelo SP, Mahoney MR, Van Tine BA et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 19(3), 416–426 (2018).Crossref, Medline, Google Scholar7. Toulmonde M, Penel N, Adam J et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 4(1), 93–97 (2018).Crossref, Medline, Google Scholar8. Wilky BA, Trucco MM, Kolonias D et al. A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS). J. Clin. Oncol. 36(Suppl. 15), S11547–S11547 (2018).Crossref, Google Scholar9. Wang D-R, Wu X-L, Sun Y-L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Sig. Transduct. Target Ther. 7(1), 1–27 (2022).Crossref, Medline, Google Scholar10. Guan L, Palmeri M, Groisberg R. Cutaneous angiosarcoma: a review of current evidence for treatment with checkpoint inhibitors. Front. Med. (Lausanne) 10, 1090168 (2023).Crossref, Medline, Google Scholar11. Espejo-Freire AP, Elliott A, Rosenberg A et al. Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis. Cancers 13(19), 4816 (2021).Crossref, Medline, CAS, Google Scholar12. Hamacher R, Kämpfe D, Reuter-Jessen K et al. Dramatic response of a PD-L1-positive advanced angiosarcoma of the scalp to pembrolizumab. JCO Precis. Oncol. 2, 1–7 (2018).Medline, Google Scholar13. Nathenson MJ, Hornick JL. Complete pathologic response to pembrolizumab in a patient with cutaneous angiosarcoma: case report. J. Hematol. Oncol. Pharm. 12(5), 278–282 (2022).Google Scholar14. Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS. Angiosarcoma treated successfully with anti-PD-1 therapy – a case report. J. Immunother. Cancer 5(1), 58 (2017).Crossref, Medline, Google Scholar15. Hofer S, Zeidler K, Schipf A, Kempf W, Zimmermann D, Aebi S. Angiosarcoma of the scalp responding to nivolumab: a case report. Br. J. Dermatol. 179(2), 530–531 (2018).Medline, CAS, Google Scholar16. Florou V, Rosenberg AE, Wieder E et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J. Immunother. Cancer 7, 1–8 (2019).Medline, Google Scholar17. Rosenbaum E, Antonescu CR, Smith S et al. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. J. Immunother. Cancer 10(4), e004149 (2022).Crossref, Medline, Google Scholar18. Ravi V, Subramaniam A, Zheng J et al. Clinical activity of checkpoint inhibitors in angiosarcoma: a retrospective cohort study. Cancer 128(18), 3383–3391 (2022).Crossref, Medline, CAS, Google Scholar19. Wagner MJ, Othus M, Patel SP et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). J. Immunother. Cancer 9(8), e002990 (2021).Crossref, Medline, Google Scholar20. Seong G, D'Angelo SP. New therapeutics for soft tissue sarcomas: overview of current immunotherapy and future directions of soft tissue sarcomas. Front. Oncol. 13, 1150765 (2023).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Ahead of Print STAY CONNECTED Metrics Downloaded 0 times History Received 26 May 2023 Accepted 25 July 2023 Published online 10 August 2023 Information© 2023 Future Medicine LtdKeywordsangiosarcomacancercheckpointimmunotherapysarcomasoft tissueFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.No writing assistance was utilized in the production of this manuscript.PDF download